Uppsala 29th July 2017


Nanexa upscales the PharmaShell® process


During the spring, Nanexa has scaled up the PharmaShell® process and can now produce ten times more material than in previous lab scale. During this upscale, we have introduced a process that is easier to automate. We estimate that further up-scaling to commercial production process will be relatively easy when the need arises.

Pharmaceutical companies have expressed desire to see results from upscaling and the present scale is fully sufficient to carry out more extensive pre-clinical and clinical studies.


Nanexa’s CEO David Westberg comments:

“During my contacts with pharmaceutical companies, a recurring issue has been our ability to scale up the PharmaShell® process. We have been confident in the assurance that the upscaling is possible and now it has also been shown. This means clear marketing benefits and greater opportunities to conduct extensive studies. ”


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se



About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.